{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:35:42Z","timestamp":1784000142560,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jemermed.2025.05.013","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:51:08Z","timestamp":1749005468000},"page":"24-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prothrombin Complex Concentrate in Direct Oral Anticoagulant Reversal: A Systematic Scoping Review"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-6985","authenticated-orcid":false,"given":"Nazedah Ain","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaa Yinn","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayati Alwani","family":"Yahaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Yee","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu Lynn","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jivanraj","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jemermed.2025.05.013_bib0001","first-page":"175","article-title":"The evolution of anticoagulant therapy","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.jemermed.2025.05.013_bib0002","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1177\/0885066619882909","article-title":"Four-factor prothrombin complex concentrate for the reversal of direct oral anticoagulants","volume":"36","author":"Zada","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0003","unstructured":"Andexxa [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals Inc; 2018."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0004","unstructured":"Praxbind [prescribing information]. Ridgefield, CT 06877 USA:Boehringer Ingelheim Pharmaceuticals, Inc. 2015."},{"issue":"55","key":"10.1016\/j.jemermed.2025.05.013_bib0005","article-title":"The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review","volume":"11","author":"Hoffman","year":"2018","journal-title":"Int J Emerg Med"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0006","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1002\/ajh.23202","article-title":"Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors","volume":"87","author":"Kaatz","year":"2012","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jemermed.2025.05.013_bib0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5694\/mja12.10614","article-title":"Gallus AS. An update of consensus guidelines for warfarin reversal","volume":"198","author":"Tran","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0008","first-page":"26","article-title":"New agents for DOAC reversal: a practical management review","volume":"29","author":"White","year":"2022","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0009","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.15808","article-title":"Haematological management of major bleeding associated with direct oral anticoagulants \u2013 UK experience","volume":"185","author":"Green","year":"2019","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.jemermed.2025.05.013_bib0010","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jemermed.2025.05.013_bib0011","first-page":"696","article-title":"Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy","volume":"38","author":"Awad","year":"2013","journal-title":"P T"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0012","first-page":"721","article-title":"Prothrombin complex concentrates [Internet]. First edit. Transfusion Medicine and Hemostasis: clinical and Laboratory Aspects","author":"Kempton","year":"2009","journal-title":"Elsevier Inc."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0013","unstructured":"Feiba [prescribing information]. Lexington USA:Takeda Pharmaceuticals U.S.A., Inc. 2013."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0014","unstructured":"Kcentra [prescribing information]. Marburg Germany: CSL Behring. 2013."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0015","unstructured":"Beriplex. [prescribing information]. Ottawa Canada: CSL Behring. 2019."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0016","unstructured":"Octaplex. [prescribing information]. Vienna Austria: Octapharma Pharmazeutika Produktionsges.m.b.H. 2023."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0017","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.jemermed.2025.05.013_bib0019","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.jemermed.2025.05.013_bib0021","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0885066618800657","article-title":"Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients","volume":"35","author":"Allison","year":"2018","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0022","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0023","article-title":"A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage","author":"Berger","year":"2019","journal-title":"J Intensive Care Med"},{"issue":"1","key":"10.1016\/j.jemermed.2025.05.013_bib0024","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","article-title":"Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products","volume":"51","author":"Castillo","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2019.01.008","article-title":"Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage","author":"Dybdahl","year":"2019","journal-title":"Am J Emerg Med [Internet]"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0026","article-title":"Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding","author":"Korobey","year":"2020","journal-title":"Neurocrit Care [Internet]"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0027","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa Inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jemermed.2025.05.013_bib0028","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0897190020907012","article-title":"Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor\u2013Associated Acute Major Bleeding: a Case Series","volume":"34","author":"Reynolds","year":"2020","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0029","article-title":"Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate","author":"Sheikh-Taha","year":"2018","journal-title":"Intern Emerg Med [Internet]"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study","author":"Smith","year":"2019","journal-title":"J Thromb Thrombolysis [Internet]"},{"issue":"34","key":"10.1016\/j.jemermed.2025.05.013_bib0031","first-page":"1","article-title":"Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors","volume":"6","author":"Tao","year":"2018","journal-title":"J Intensive Care"},{"issue":"5","key":"10.1016\/j.jemermed.2025.05.013_bib0032","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0885066620916706","article-title":"Comparison of low- versus high-dose four-factor prothrombin complex concentrate (4F-PCC) for factor Xa inhibitor\u2013associated bleeding: a retrospective study","volume":"36","author":"Wilsey","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0033","first-page":"1","article-title":"The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: an observational analysis","author":"Zheng","year":"2020","journal-title":"Transfus Med"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0034","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ALN.0000000000001631","article-title":"Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: an Observational Registry Analysis","volume":"127","author":"Albaladejo","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0035","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/rth2.12336","article-title":"Emergencies on direct oral anticoagulants: management, outcomes, and laboratory effects of prothrombin complex concentrate","volume":"4","author":"Bavalia","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"10.1016\/j.jemermed.2025.05.013_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-017-0158-9","article-title":"Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial","volume":"16","author":"Schenk","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0037","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.15705","article-title":"Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding","volume":"184","author":"Arachchillage","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jemermed.2025.05.013_bib0038","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: a Prospective Cohort Study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0039","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical non-patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0040","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1160\/TH16-12-0946","article-title":"Clinical impact of major bleeding in patients with venous thrombo -embolism treated with factor Xa inhibitors or vitamin K antagonists an individual patient data meta-analysis","volume":"117","author":"Bleker","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0041","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/jth.13148","article-title":"Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH","volume":"14","author":"Khorsand","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jemermed.2025.05.013_bib0042","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2522\/ptj.20130199","article-title":"Validity of the AM-PAC \u201c6-Clicks\u201d Inpatient daily activity and basic mobility short forms","volume":"94","author":"Jette","year":"2014","journal-title":"Phys Ther"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0043","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/STROKEAHA.118.023840","article-title":"Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage","volume":"50","author":"Bower","year":"2019","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.jemermed.2025.05.013_bib0044","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jemermed.2025.05.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12518","article-title":"A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding","volume":"5","author":"Jaspers","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0046","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"5","key":"10.1016\/j.jemermed.2025.05.013_bib0047","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/ALN.0000000000001856","article-title":"Reversing dabigatran anticoagulation with prothrombin complex concentrate versus idarucizumab as part of multimodal hemostatic intervention in an animal model of polytrauma","volume":"127","author":"Honickel","year":"2017","journal-title":"Anesthesiology"},{"issue":"8","key":"10.1016\/j.jemermed.2025.05.013_bib0048","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2025.05.013_bib0049","unstructured":"McGlasson D.L., Fritsma G. Factor X or anti-Xa Assay. Which Do I Use? [Internet]. Available from: https:\/\/diapharma.com\/wp-content\/uploads\/2016\/01\/KDPGFX_FX_vs_anti-Xa_assay_ML-01-00012REV01.pdf."},{"key":"10.1016\/j.jemermed.2025.05.013_bib0050","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-62703-339-8_19","article-title":"Anti-factor Xa (Anti-Xa) assay","author":"Newall","year":"2013"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467925002240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467925002240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:29:07Z","timestamp":1762309747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467925002240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S0736467925002240"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2025.05.013","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prothrombin Complex Concentrate in Direct Oral Anticoagulant Reversal: A Systematic Scoping Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2025.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}